Why Quoin Pharmaceuticals Ltd ADR (QNRX) Stock Is Rising
As of 2026-11-12, Quoin Pharmaceuticals Ltd ADR (QNRX) has a next-year EPS growth estimate of 53.05%. Featured in 4 EPS revision reports, most recently on 2026-07-02.
Why QNRX Stock Is Rising
- +EPS Estimate Upgraded: Analysts raised Quoin Pharmaceuticals Ltd ADR's next-year EPS growth estimate from 54.09% to 55.56% on 2026-11-06.
- ·Current-Year Growth: Projected at 65.17%, supporting the forward estimate revision.
News Context
The primary structural driver appears to be the Nov. 6, 2026 analyst
Generated 2026-11-11 · news as of 2026-11-10
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 53.05%
- EPS growth this year
- 65.17%
- EPS next quarter (est)
- -$0.91
- Last price
- $3.75
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-11-12 | 53.05% | 65.17% | -$0.91 | $3.75 |
| 2026-11-11 | 53.05% | 65.17% | -$0.91 | $3.76 |
| 2026-11-10 | 53.42% | 64.83% | -$0.93 | $3.73 |
| 2026-11-09 | 55.56% | 62.60% | -$1.09 | $3.90 |
| 2026-11-07 | 55.56% | 62.60% | -$1.09 | $3.65 |
| 2026-11-06 | 55.56% | 62.60% | -$1.09 | $3.65 |
| 2026-11-05 | 54.09% | 61.47% | -$1.13 | $3.85 |
| 2026-11-04 | 55.45% | 58.95% | -$1.52 | $4.02 |
| 2026-11-03 | 55.45% | 58.95% | -$1.52 | $3.93 |
| 2026-11-02 | 55.45% | 58.95% | -$1.52 | $4.02 |
| 2026-10-31 | 55.45% | 58.95% | -$1.52 | $4.54 |
| 2026-10-30 | 55.45% | 58.95% | -$1.52 | $4.54 |
| 2026-10-29 | 55.45% | 58.95% | -$1.52 | $4.15 |
| 2026-10-28 | 55.45% | 58.95% | -$1.52 | $4.11 |
| 2026-10-27 | 55.45% | 58.95% | -$1.52 | $4.05 |
| 2026-10-26 | 55.45% | 58.95% | -$1.52 | $4.01 |
| 2026-10-23 | 55.45% | 58.95% | -$1.52 | $4.02 |
| 2026-10-22 | 55.45% | 58.95% | -$1.52 | $4.01 |
| 2026-10-21 | 55.45% | 58.95% | -$1.52 | $3.99 |
| 2026-10-20 | 55.45% | 58.95% | -$1.52 | $4.04 |
| 2026-10-19 | 55.45% | 58.95% | -$1.52 | $3.98 |
| 2026-10-16 | 59.08% | 56.84% | -$1.61 | $3.90 |
| 2026-10-15 | 59.08% | 56.84% | -$1.61 | $4.03 |
| 2026-10-14 | 59.08% | 56.84% | -$1.61 | $4.10 |
| 2026-10-13 | 59.08% | 56.84% | -$1.61 | $4.15 |
| 2026-10-12 | 59.08% | 56.84% | -$1.61 | $4.36 |
| 2026-10-11 | 56.67% | 58.72% | -$1.53 | $4.50 |
| 2026-10-10 | 56.67% | 58.72% | -$1.53 | $4.50 |
| 2026-10-09 | 56.67% | 58.72% | -$1.53 | $4.50 |
| 2026-10-08 | 56.67% | 58.72% | -$1.53 | $4.55 |
Reports Featuring QNRX
- 2026-07-02
Top Stock Gainers Driven by EPS Estimate Revisions: QNRX Up 40.9%, IOT Up 24% - July 2, 2026
- 2026-07-01
Top EPS Revision-Driven Movers: QNRX Surges +44.9% as NMAX Sees 376.9% Growth Estimate
- 2026-06-30
QNRX surges 48.9% as EPS revision signal precedes price breakout; HELP, ACMR also climb
- 2026-06-29
EPS Revision Bonanza: LILA +61%, HELP +47%, BDSX +42% Lead Surge
Recent News
- Quoin Pharmaceuticals' Latest NETHERTON NOW Video Details the Life of a Family Living with Netherton SyndromeGlobeNewswire
- Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI as the Proposed Brand Name for QRX003 for Netherton SyndromeGlobeNewswire
- Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial ResultsGlobeNewswire
- Quoin Pharmaceuticals Provides Clinical and Regulatory Update from Constructive Type C Meeting with U.S. FDA for QRX003 in Netherton SyndromeGlobeNewswire
Screen Performance
Aggregate stats across all 2145 tickers our top-EPS-revision screen has flagged over the past 225 days.
- Median return since detection
- -2.9%
- % of tickers in the green
- 43%
- Median return on winners
- +22.8%
- Large revisions captured
- 2246
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
Why did Quoin Pharmaceuticals Ltd ADR (QNRX) stock go up recently?▾
Quoin Pharmaceuticals Ltd ADR (QNRX) stock has risen following an analyst upgrade of its next-year EPS growth estimate from 54.09% to 55.56% on 2026-11-06. EPS estimate upgrades are among the strongest leading indicators of stock outperformance.
What is Quoin Pharmaceuticals Ltd ADR's next-year EPS growth estimate?▾
As of 2026-11-12, Quoin Pharmaceuticals Ltd ADR (QNRX) has a next-year EPS growth estimate of 53.05%, based on analyst consensus.
When was the latest EPS estimate revision for QNRX?▾
The most recent revision occurred on 2026-11-11, when analysts adjusted the next-year EPS growth estimate from 53.42% to 53.05%.
What sector and industry does Quoin Pharmaceuticals Ltd ADR belong to?▾
Quoin Pharmaceuticals Ltd ADR operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. QNRX appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Quoin Pharmaceuticals Ltd ADR (QNRX) appears here because it was detected by our daily top-EPS-revision-performer screen.